Analyst Price Targets — WGS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 4, 2026 10:44 am | Kyle Mikson | Canaccord Genuity | $90.00 | $67.86 | StreetInsider | GeneDx (WGS) PT Raised to $90 at Canaccord |
| June 29, 2026 11:01 am | — | Guggenheim | $74.00 | $69.82 | TheFly | GeneDx price target raised to $74 from $70 at Guggenheim |
| June 23, 2026 10:57 am | David Westenberg | Piper Sandler | $63.00 | $55.42 | TheFly | GeneDx price target raised to $63 from $50 at Piper Sandler |
| May 5, 2026 12:09 pm | Bill Bonello | Craig-Hallum | $85.00 | $35.59 | TheFly | GeneDx price target lowered to $85 from $153 at Craig-Hallum |
| May 5, 2026 11:35 am | — | BTIG | $90.00 | $67.93 | TheFly | GeneDx price target lowered to $90 from $170 at BTIG, removed from Top Picks |
| May 5, 2026 11:21 am | — | Guggenheim | $70.00 | $67.93 | TheFly | GeneDx price target lowered to $70 from $100 at Guggenheim |
| May 5, 2026 10:46 am | Kyle Mikson | Canaccord Genuity | $75.00 | $67.93 | TheFly | GeneDx price target lowered to $75 from $100 at Canaccord |
| May 5, 2026 10:20 am | Brandon Couillard | Wells Fargo | $75.00 | $67.93 | TheFly | GeneDx price target lowered to $75 from $155 at Wells Fargo |
| April 20, 2026 1:08 pm | — | Canaccord Genuity | $100.00 | $67.72 | TheFly | GeneDx price target raised to $100 from $70 at Canaccord |
| February 24, 2026 12:45 pm | Mark Massaro | BTIG | $170.00 | $87.08 | TheFly | GeneDx price target lowered to $170 from $200 at BTIG |
Latest News for WGS
GAITHERSBURG, Md.--(BUSINESS WIRE)--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity.
On August 26, 2026, GeneDx Holdings Corp (WGS) shares rose 3.3%, bringing the current price to $90.28. The stock is trading within a 52-week range of $32.21 to
Bears have piled into a familiar batch of volatile, heavily bet-against names, and nowhere is the wager bigger than on Venture Global, Inc. (NYSE:VG). More than 80% of its float is sold short, the steepest ratio on the market's current top-10 short-interest list, per Benzinga Pro data.
[url="]GeneDx[/url] (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new data publish
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Seattle Children's show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for WGS.
U.S. House Trading
No House trades found for WGS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.